# Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

> **NCT03598244** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- Recurrent Diffuse Intrinsic Pontine Glioma
- Recurrent Malignant Glioma
- Recurrent Medulloblastoma
- Recurrent Primary Central Nervous System Neoplasm
- Refractory Diffuse Intrinsic Pontine Glioma
- Refractory Malignant Glioma
- Refractory Medulloblastoma
- Refractory Primary Central Nervous System Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Savolitinib
- **PROCEDURE:** X-Ray Imaging

## Key facts

- **NCT ID:** NCT03598244
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-27
- **Primary completion:** 2025-04-14
- **Final completion:** 2026-04-14
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03598244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03598244, "Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03598244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*